Videos

Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 years old.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.

Some cancer statistics may reflect 'backwards-looking data', making it important to stay up to date on reliable information and happenings in the space.

Dr. Sheri Yolanda Prentiss discusses the importance of seeking early intervention to detect lymphedema following cancer care.

Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early detection of the essence.

Radiation therapy plays an important role in reducing the risk of cancer recurrence for patients with breast cancer undergoing breast reconstruction.

It is important to recognize Kidney Cancer Awareness Month as a time to get involved, as more than 600,000 people in the U.S. live with kidney cancer.

Shorter radiation courses may improve breast reconstruction outcomes without increasing complications, according to Dr. Reshma Jagsi.

Biomarkers can shape a breast cancer treatment plan, Andy Guinigundo explained in an interview with CURE.

Colorectal cancer is on the rise among younger adults, although potential explanations for the cause of this trend are likely years away.

Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.

Machine learning model improves transplant risk assessment for patients with myelofibrosis, helping clinicians make informed decisions, as per an expert.

Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.

There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.

Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.

Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.

CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.

Dr. Regina Hampton discusses key factors contributing to this disparity, and how healthcare systems can address these challenges.

CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.

Sid Sadler discusses kidney cancer awareness, patient advocacy and the need for specialized care to improve access to treatments and clinical trials.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Panelists discuss how multiple myeloma support resources range from formal organizations like the International Myeloma Foundation and Multiple Myeloma Research Foundation to online patient communities, hospital-based support groups, and specialized social media networks, with advice for newly relapsed patients emphasizing the importance of allowing emotional processing before taking action, seeking second opinions from myeloma specialists, asking detailed questions about all available options including clinical trials, connecting with patients who’ve undergone similar treatments, maintaining hope amid setbacks, and recognizing that relapses, while challenging, often open doors to novel therapeutic approaches that can effectively control the disease for extended periods.

Panelists discuss how caregivers supporting loved ones with late-line relapsed/refractory multiple myeloma (RRMM) should prioritize both patient and self-care by establishing sustainable support systems, maintaining open communication with the health care team, educating themselves about treatment options while acknowledging emotional boundaries, creating practical organizational systems for medication management and appointment tracking, seeking respite care when needed, connecting with caregiver support groups for shared experiences, participating in decision-making without overshadowing the patient’s voice, preparing contingency plans for complications, and finding moments of normalcy and joy amid the challenges of advanced disease management.

Panelists discuss how effective communication with medical teams in advanced multiple myeloma requires proactive strategies including preparing prioritized question lists before appointments, bringing a designated note-taking advocate to consultations, utilizing patient portals for nonurgent concerns, clearly articulating quality of life impacts rather than just symptom presence, requesting dedicated time for treatment planning discussions, recording conversations (with permission) for later review, maintaining symptom diaries with specific details, and establishing relationships with nurse navigators who can facilitate more timely responses—approaches that collectively ensure patient needs are comprehensively addressed despite the complex nature of late-line treatment decisions.

Panelists discuss how patients and caregivers at the late-line treatment stage commonly struggle with profound concerns about diminishing treatment options, increased uncertainty about prognosis, managing complex and often cumulative side effects, financial toxicity from years of therapy, caregiver burnout, practical challenges of more frequent hospitalizations, anxiety about becoming refractory to novel agents, navigating clinical trial eligibility, maintaining hope while being realistic and balancing aggressive treatment approaches with quality of life considerations as therapeutic choices narrow.